Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- PMID: 31339677
- DOI: 10.1056/NEJMoa1902824
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
Abstract
Background: Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries.
Methods: We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more per milliliter. The primary end point was the percentage of patients with a 48-week HIV-1 RNA level of less than 50 copies per milliliter (as determined with the Snapshot algorithm from the Food and Drug Administration; noninferiority margin, -10 percentage points). We report the primary (48-week) efficacy and safety data.
Results: A total of 1053 patients underwent randomization from February 2017 through May 2018. More than 99% of the patients were black, and 59% were female. The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter. At week 48, the percentage of patients with an HIV-1 RNA level of less than 50 copies per milliliter was 84% in the TAF-based group, 85% in the TDF-based group, and 79% in the standard-care group, findings that indicate that the DTG-containing regimens were noninferior to the standard-care regimen. The number of patients who discontinued the trial regimen was higher in the standard-care group than in the other two groups. In the per-protocol population, the standard-care regimen had equivalent potency to the other two regimens. The TAF-based regimen had less effect on bone density and renal function than the other regimens. Weight increase (both lean and fat mass) was greatest in the TAF-based group and among female patients (mean increase, 6.4 kg in the TAF-based group, 3.2 kg in the TDF-based group, and 1.7 kg in the standard-care group). No resistance to integrase inhibitors was identified in patients receiving the DTG-containing regimens.
Conclusions: Treatment with DTG combined with either of two tenofovir prodrugs (TAF and TDF) showed noninferior efficacy to treatment with the standard-care regimen. There was significantly more weight gain with the DTG-containing regimens, especially in combination with TAF, than with the standard-care regimen. (ADVANCE ClinicalTrials.gov number, NCT03122262.).
Copyright © 2019 Massachusetts Medical Society.
Comment in
-
Global HIV Treatment - Turning Headwinds to Tailwinds.N Engl J Med. 2019 Aug 29;381(9):873-874. doi: 10.1056/NEJMe1909363. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31339675 No abstract available.
Similar articles
-
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7. Lancet. 2021. PMID: 33812487 Free PMC article. Clinical Trial.
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1. Lancet HIV. 2020. PMID: 33010240 Clinical Trial.
-
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.Int J Infect Dis. 2020 Apr;93:108-117. doi: 10.1016/j.ijid.2020.01.035. Epub 2020 Jan 25. Int J Infect Dis. 2020. PMID: 31988012 Review.
-
Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.Expert Opin Pharmacother. 2020 Mar;21(4):389-397. doi: 10.1080/14656566.2020.1713096. Epub 2020 Jan 20. Expert Opin Pharmacother. 2020. PMID: 31957507 Free PMC article. Review.
-
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541. N Engl J Med. 2013. PMID: 24195548 Clinical Trial.
Cited by
-
Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy.Antioxidants (Basel). 2024 Apr 26;13(5):518. doi: 10.3390/antiox13050518. Antioxidants (Basel). 2024. PMID: 38790623 Free PMC article.
-
Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease.Circ Res. 2024 May 24;134(11):1515-1545. doi: 10.1161/CIRCRESAHA.124.323891. Epub 2024 May 23. Circ Res. 2024. PMID: 38781301 Free PMC article. Review.
-
Exercise to Prevent Accelerated Vascular Aging in People Living With HIV.Circ Res. 2024 May 24;134(11):1607-1635. doi: 10.1161/CIRCRESAHA.124.323975. Epub 2024 May 23. Circ Res. 2024. PMID: 38781293 Review.
-
Trends in body mass index in the pre-dolutegravir period in South Africa.South Afr J HIV Med. 2024 Apr 23;25(1):1523. doi: 10.4102/sajhivmed.v25i1.1523. eCollection 2024. South Afr J HIV Med. 2024. PMID: 38725702 Free PMC article.
-
Adults with Perinatally Acquired HIV; Emerging Clinical Outcomes and Data Gaps.Trop Med Infect Dis. 2024 Apr 3;9(4):74. doi: 10.3390/tropicalmed9040074. Trop Med Infect Dis. 2024. PMID: 38668535 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials